Literature DB >> 11095466

High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves' disease treated with propylthiouracil.

H Sato1, M Hattori, M Fujieda, S Sugihara, H Inomata, M Hoshi, S Miyamoto.   

Abstract

Propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-related vasculitis and nephritis were recently reported in about 30 patients with hyperthyroidism. The objective of this study was to clarify the prevalence of ANCA and the relationship between ANCA and thyroid antibodies in children with Graves' disease. Titers of myeloperoxidase (MPO)-ANCA in sera of 51 patients with childhood onset Graves' disease (16 before treatment, 25 and 10 treated with PTU and methimazole, respectively) were measured by enzyme-linked immunosolvent assay. Antithyroglobulin antibodies (TGAbs) and antithyroperoxidase antibodies (TPOAbs) were also measured by RIA in 25 PTU-treated patients. No patients had clinical manifestations of vasculitis and nephritis. MPO-ANCA was positive in 6.7% of patients before treatment and in 64.0% of those treated with PTU and in none of those treated with methimazole. MPO-ANCA had a significantly positive correlation with TGAbs (P < 0.05) and no significant correlation with TPOAbs. These findings show the high prevalence of the MPO-ANCA positivity in PTU-treated childhood onset Graves' disease, suggesting that PTU may not be preferred as the first line for the treatment of children with Graves' disease. The significant correlation between MPO-ANCA and TGAbs indicates that the severity of Graves' disease may be a factor responsible for the MPO-ANCA positivity. The cross-reactivity between MPO-ANCA and TPOAbs may not play a role in the high prevalence of MPO-ANCA in the patients exposed to PTU.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11095466     DOI: 10.1210/jcem.85.11.7000

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  23 in total

Review 1.  Drug-induced vasculitis.

Authors:  Marta Lucia Cuellar
Journal:  Curr Rheumatol Rep       Date:  2002-02       Impact factor: 4.592

Review 2.  ANCA-associated vasculitides-lessons from the adult literature.

Authors:  Joannis Vamvakopoulos; Caroline O Savage; Lorraine Harper
Journal:  Pediatr Nephrol       Date:  2010-04-01       Impact factor: 3.714

3.  A comparison of antineutrophil cytoplasmic antibody prevalence in patients treated and untreated for hyperthyroidism.

Authors:  Turan Calhan; Ebubekir Senateş; Egemen Cebeci; Sayid Shafi Zuhur; Fatma Ozbakır; Uğur Görpe
Journal:  Endocrine       Date:  2010-07-11       Impact factor: 3.633

4.  Vasculitis and anti-thyroid medication.

Authors:  Sofia Lionaki; Susan L Hogan; Ronald J Falk; Melanie S Joy; Caroline E Jennette; Patrick H Nachman; J Charles Jennette
Journal:  Nephrol Dial Transplant       Date:  2007-12-21       Impact factor: 5.992

5.  [Secondary vasculitides and vasculitis mimics].

Authors:  K de Groot; E Märker-Hermann
Journal:  Z Rheumatol       Date:  2012-11       Impact factor: 1.372

6.  Arthritis associated with antithyroid therapy in a 15-year-old girl.

Authors:  Wieteke M Ploegstra; Ronald P Boontje; Arvid W A Kamps
Journal:  J Pediatr Pharmacol Ther       Date:  2011-04

Review 7.  Neutrophil functions of patients with vasculitis related to myeloperoxidase-specific anti-neutrophil antibody.

Authors:  K Suzuki
Journal:  Int J Hematol       Date:  2001-08       Impact factor: 2.490

8.  A Case of p-ANCA-Positive Propylthiouracil-Induced Pyoderma Gangrenosum.

Authors:  Jong Won Seo; Hyun Ho Son; Joon Hee Choi; Sook Kyung Lee
Journal:  Ann Dermatol       Date:  2010-02-28       Impact factor: 1.444

9.  Benzylthiouracil-induced glomerulonephritis.

Authors:  Sihem Trimeche Ajmi; Rim Braham; Sarra Toumi; Molka Chadli Chaieb; Amel Maaroufi; Koussay Ach; Larbi Chaieb
Journal:  Case Rep Med       Date:  2009-07-06

10.  Churg-Strauss Syndrome following PTU Treatment.

Authors:  R A M Quax; A J G Swaak; M G A Baggen
Journal:  Int J Rheumatol       Date:  2009-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.